Stay updated on PD-1/CD137 Blockade with Cell Therapy in Melanoma Clinical Trial

Sign up to get notified when there's something new on the PD-1/CD137 Blockade with Cell Therapy in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the PD-1/CD137 Blockade with Cell Therapy in Melanoma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    7 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the Pilot Clinical Trial combining PD-1 Blockade, CD137 Agonism, and Adoptive Cell Therapy for Metastatic Melanoma, specifically related to the safety, side effects, and benefits of tumor-infiltrating lymphocytes (TILs) when given with the drug nivolumab.
    Difference
    0.1%
    Check dated 2024-06-06T14:32:16.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change provides a more detailed explanation of eligibility criteria, including examples such as a person's general health condition or prior treatments.
    Difference
    50%
    Check dated 2024-05-22T20:32:55.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:36:03.000Z thumbnail image

Stay in the know with updates to PD-1/CD137 Blockade with Cell Therapy in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the PD-1/CD137 Blockade with Cell Therapy in Melanoma Clinical Trial page.